A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Inclusion Criteria:

• Male and female ≥50 to <80 years of age at Screening Part II

• Lp(a) ≥175 nmol/L at the screening visit, measured at the Central laboratory

• Mild or moderate calcific aortic valve stenosis

• At the randomization visit, participant must be optimally treated for existing CVrisk factors

Exclusion Criteria:

• Severe calcific aortic valve stenosis

• Uncontrolled hypertension

• History of malignancy of any organ system

• History of hemorrhagic stroke or other major bleeding

• Platelet count ≤ LLN

• Active liver disease or hepatic dysfunction

• Significant kidney disease

• Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply